Takeda’s Millennium Seeks Modest Acquisitions, But Could Go Bigger
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical has freed its U.S.-based Millennium biotech unit to seek its own mergers and acquisitions among the more modest players in the drug making industry. CEO Deborah Dunshire said in an interview that Millennium is not likely to try to acquire a large company, noting Takeda's own avoidance of such deals. She said a Millennium M&A is likely to center on "smaller, single-product acquisitions." She did not, however, rule out a larger transaction as big as the $10 billion range. (Click here for more - a subscription may be required
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.